Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Harrison on visceral fat

<< Previous

Bullboard Posts

Next >>

Post by qwerty22on Sep 19, 2021 2:14am

249 Views

Post# 33884119

Harrison on visceral fat

https://surfingnash.com/s2-e46-highlights-from-paris-nash/

Start at 17min. They talk about the Paris NASH and somebody who presented on NASH and visceral fat. Harrison brings up tesamorelin. It's a short chat (finishes around 21min) but making similar points Grinspoon made about why Tesamorelin might be a new way to look at the problem.

(I guess Harrison was at Paris NASH at the time of the thtx KOL event)

<< Previous

Bullboard Posts

Next >>

98% energy efficiency: How Acceleware's EM Technology is transforming heat solutions